Jianrong Li

Measles virus (MeV) has been an excellent vector platform for delivering vaccines against many pathogens because of its high safety and efficacy, and induction of long‐lived immunity. Early in the COVID‐19 pandemic, a recombinant MeV (rMeV) expressing the prefusion full‐length spike protein stabilized by two prolines (TMV‐083) was developed and tested in phase 1 and 1/2 clinical trials but was discontinued because of insufficient immunogenicity and a low seroconversion rate in adults. Here, we compared the immunogenicity of rMeV expressing a soluble prefusion spike (preS) protein stabilized by two prolines (rMeV‐preS‐2P) with a rMeV expressing a soluble preS protein stabilized by six prolines (rMeV‐preS‐6P). We found that rMeV‐preS‐6P expressed approximately five times more preS than rMeV‐preS‐2P in cell culture. Importantly, rMeV‐preS‐6P induced 30‐60 and six times more serum immunoglobulin G and neutralizing antibody than rMeV‐preS‐2P, respectively, in IFNAR −/− mice. IFNAR −/− mice immunized with rMeV‐preS‐6P were completely protected from challenge with a mouse‐adapted SARS‐CoV‐2, whereas those immunized with rMeV‐preS‐2P were partially protected. In addition, hamsters immunized with rMeV‐preS‐6P were completely protected from the challenge with a Delta variant of SARS‐CoV‐2. Our results demonstrate that rMeV‐preS‐6P is significantly more efficacious than rMeV‐preS‐2P, highlighting the value of using preS‐6P as the antigen for developing vaccines against SARS‐CoV‐2.